Paper · 22805291

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante JR and 18 others. Lancet Oncol, 2012. Cited by 478 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Papers, record 22805291. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22805291

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.; PubMed
Journal: Lancet Oncol; PubMed
Year: 2012; PubMed
Publication types: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Webcast; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/22805291/; PubMed
DOI: https://doi.org/10.1016/s1470-2045(12)70270-x; PubMed
The journal: https://conductscience.org/library/journal-index/100957246; PubMed
Citations, by iCite: 478; iCite
Relative citation ratio, by iCite: 11.7; iCite
Revised in PubMed: 2022-04-16; PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Infante JR	Jeffrey R
2	Fecher LA	Leslie A
3	Falchook GS	Gerald S
4	Nallapareddy S	Sujatha
5	Gordon MS	Michael S
6	Becerra C	Carlos
7	DeMarini DJ	Douglas J
8	Cox DS	Donna S
9	Xu Y	Yanmei
10	Morris SR	Shannon R

1 to 10 of 19Source PubMed

See all 19 authors

Topics26

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Agents	Major topic
MAP Kinase Kinase 1	Major topic
MAP Kinase Kinase 2	Major topic
Neoplasms	Major topic
Protein Kinase Inhibitors	Major topic
Pyridones	Major topic
Pyrimidinones	Major topic
Administration, Oral
Adult
Aged
Aged, 80 and over
Area Under Curve
Biopsy
Drug Administration Schedule
Drug Monitoring
Female
Half-Life
Humans
Male
Maximum Tolerated Dose
Metabolic Clearance Rate
Middle Aged
Molecular Targeted Therapy
Treatment Outcome
United States
Young Adult

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT00687622	Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma	Background	Yes	ClinicalTrials.gov
NCT04943224	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients	Background		ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	22,805,290	The coming of age of MEK.	https://conductscience.org/library/papers/22805290

Source PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by298

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 478 citations.

PMID	Title	Journal	Year	In Papers	Source
42,857,105	rAAV-mediated multi-miRNA delivery targeting MAPK pathway suppresses laser-induced choroidal neovascularization in mice.	Mol Ther Nucleic Acids	2026	https://conductscience.org/library/papers/42857105	PubMed
42,757,853	Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.	Cancer Discov	2026	https://conductscience.org/library/papers/42757853	PubMed
42,608,562	Decoction-derived bioactive nanoparticles of Lycopodium japonicum Thunb. attenuate knee osteoarthritis by regulating MAPK/ERK signaling.	Naunyn Schmiedebergs Arch Pharmacol	2026	https://conductscience.org/library/papers/42608562	PubMed
42,478,961	Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass.	Cancer Res	2026	https://conductscience.org/library/papers/42478961	PubMed
42,246,190	Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).	Int J Oncol	2026	https://conductscience.org/library/papers/42246190	PubMed
42,204,589	Ras-MAPK inhibition induces AXIN1 loss in colorectal cancer by mTOR associated suppression of protein synthesis.	Cell Commun Signal	2026	https://conductscience.org/library/papers/42204589	PubMed
42,094,384	Macrophage-Derived PDGF-BB and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer.	bioRxiv	2026	https://conductscience.org/library/papers/42094384	PubMed
42,048,384	The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.	Clin Cancer Res	2026	https://conductscience.org/library/papers/42048384	PubMed
42,021,873	Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma.	Int J Transl Med (Basel)	2025	https://conductscience.org/library/papers/42021873	PubMed
41,946,829	Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.	Br J Cancer	2026	https://conductscience.org/library/papers/41946829	PubMed

1 to 10 of 298

See all 298 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
MAP2K1	5,604	PubTator's text mining	https://conductscience.org/library/genes/5604	NCBI Gene
MAP2K2	5,605	PubTator's text mining	https://conductscience.org/library/genes/5605	NCBI Gene
MAP2K7	5,609	PubTator's text mining	https://conductscience.org/library/genes/5609	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22805291

GET https://conductscience.org/api/papers/v1/22805291/cited_by?page=2

API reference For AI assistants